US/UK/Canada

Share

Contacts

  • Hansa Biopharma AB
    Scheelevägen 22 22363 Lund, Sweden
    +46 (0) 461 656 70
    http://www.hansabiopharma.com
    • Pick a time period -
    Tags ( Active)

    Hansa Biopharma announces first patient treated in the post-authorization efficacy study (PAES) of Idefirix® (imlifidase) in highly sensitized kidney transplant patients

    · The PAES is an open-label Phase 3 study to further investigate the long-term graft survival in 50 highly sensitized patients who have undergone kidney transplantation after Idefirix® administration in the EU1 · The PAES is an obligation under the conditional marketing authorization for Idefirix® granted by the European Medicines Agency (EMA) in August 20202 · The study will provide further important insights to the Idefirix® desensitization treatment of highly sensitized kidney transplant patients Lund, Sweden, July 11, 2022. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA),

    Hansa Biopharma presented new data on imlifidase at the European Society for Organ Transplantation (ESOT) Congress

    · Hansa presented two abstracts on imlifidase, adding to the body of evidence that supports the use of imlifidase in enabling transplantation in highly sensitized patients     · Hansa also hosted a symposium at ESOT with five experts on enabling transplantation for highly sensitized patients Lund, Sweden September 1, 2021. Hansa Biopharma, “Hansa” (Nasdaq Stockholm: HNSA), the pioneer in enzyme technology for rare immunological conditions, today announced two abstracts presented at the European Society for Organ Transplantation (ESOT) Congress, August 29-September 1, 2021. The

    Hansa Biopharma announces reimbursement in the Netherlands of Idefirix[®] (imlifidase) as desensitization treatment for highly sensitized kidney transplant patients

    · Idefirix[®][▼][ ] (imlifidase) for enabling kidney transplantation in highly sensitized patients is now reimbursable and available for use in the Netherlands · Idefirix[® ]is the first and only approved medicine by the European Commision for the desensitization of highly sensitized patients prior to kidney transplantation[1]Lund, Sweden, August 2, 2021. Hansa Biopharma, “Hansa” (Nasdaq Stockholm: HNSA), the pioneer in enzyme technology for rare immunological conditions, today announces that its first-in-class treatment Idefirix[®▼] (imlifidase) is, as of August 1, reimbursable and

    Hansa Biopharma announces long term follow-up data demonstrating 3-year graft survival of 84% after imlifidase treatment and transplantation

    · Three-year overall allograft survival was 84% in crossmatch positive patients treated with imlifidase. · In patients with a cPRA of ≥99.9%, three-year allograft survival was 92% · Data published in an article accepted by the American Journal of Transplantation Lund, Sweden July 9, 2021. Hansa Biopharma, “Hansa” (Nasdaq Stockholm: HNSA), the pioneer in enzyme technology for rare immunological conditions, today announced three-year follow-up data in crossmatch positive patients who received imlifidase prior to kidney transplantation.[1] As reported in the article, which has been

    Hansa Biopharma appoints Dr. Magnus Korsgren as Head of Research & Development

    Dr Korsgren to lead the research and development of Hansa’s proprietary enzyme technology platform as the Company expands also into new therapeutic areasLund, Sweden March 1, 2021. Hansa Biopharma, the pioneer in immunomodulatory enzyme technology for rare IgG mediated diseases, today announces the appointment of Magnus Korsgren, M.D., Ph.D. as Vice President and Head of Research and Development. Dr Korsgren will lead the efforts to advance Hansa Biopharma’s pipeline of drug candidates for rare immunologic diseases based on the Company’s proprietary IgG-cleaving enzyme technology

    Bulletin from the Annual General Meeting in Hansa Biopharma AB (publ)

    The following resolutions were passed at the Annual General Meeting of Hansa Biopharma AB (publ) (the “Company”) on 22 May 2019. Resolution regarding the adoption of the income statement and the balance sheet as well as consolidated income statement and consolidated balance sheet, appropriation of result and discharge from liability The Annual General Meeting resolved to adopt the income statement and balance sheet, consolidated income statement and balance sheet for 2018. Furthermore, it was resolved that the Company’s results shall be carried forward and thus no dividend will be

    Hansa Biopharma to Present at the Cowen 39th Annual Health Care Conference

    Lund, Sweden, March 6, 2019 – Hansa Biopharma AB (NASDAQ Stockholm: HNSA), the leader in immunomodulatory enzyme technology for rare IgG-mediated diseases, announced today that Søren Tulstrup, President and CEO of Hansa Biopharma, will present at the Cowen 39th Annual Health Care Conference on Wednesday, March 13, 2019 at 9:20AM ET/ 3:20PM CET. The conference will be held at the Boston Marriott Copley Place in Boston, MA.A live webcast will be available on the Events & Webcast page of the Company's website, www.hansabiopharma.com. A replay of the presentation will be available approximately

    Hansa Biopharma Announces European Medicines Agency Accepts Marketing Authorization Application for IDEFIRIX™ (imlifidase)

    Lund, Sweden, March 1, 2019 – Hansa Biopharma AB (NASDAQ Stockholm: HNSA), the leader in immunomodulatory enzyme technology for rare IgG-mediated diseases, announced today that the European Medicines Agency (EMA) has accepted the Company’s Marketing Authorization Application (MAA) for review of IDEFIRIX™ (INN: imlifidase). Hansa is seeking approval of IDEFIRIX as a treatment to enable kidney transplantation in highly sensitized patients. IDEFIRIX is a novel antibody-degrading enzyme that eliminates immunological barriers. It is administered as a single intravenous infusion immediately prior

    Increase of number of shares and votes in Hansa Biopharma AB (publ)

    Lund, Sweden, February 28, 2019 – Hansa Biopharma AB (NASDAQ Stockholm: HNSA), the leader in immunomodulatory enzyme technology for rare IgG-mediated diseases, announced today that the Company’s number of shares and votes has changed as a result of a new issue of 50,000 ordinary shares carried out in February. The new issue was carried out as part of the completion of the Company’s warrant program 2015-2019. In addition, the Company has converted 3,075 C shares into ordinary shares under Hansa’s long-term incentive programme.As of February 28, 2019, the total number of registered and

    Hansa Biopharma Year-End Report 2018

    With positive clinical results from the Company’s lead clinical program, Hansa readies for transition to commercial-stage companyOctober – December 2018 in brief ›› To better reflect its evolution and long-term aspirations, Hansa Medical AB changed its name to Hansa Biopharma AB. The new name represents the next stage in the Company’s lifecycle and emphasizes Hansa’s focus on the development and commercialization of biopharmaceuticals. This refinement of Hansa’s profile is particularly salient as the Company continues the international expansion of its business and investor base. ›› In

    Hansa Medical to Host Conference Call to Provide Year-End Report 2018 Business Update

    Lund, Sweden, January 31, 2019 – Hansa Medical AB (publ) (Nasdaq Stockholm: HNSA) (“Hansa Medical” or the “Company”), under name change to Hansa Biopharma AB, a biopharmaceutical company focused on inhibition of immunoglobulin G (IgG)-mediated immunopathologies, today announced that Hansa Medical will publish the 2018 Year-End Report on 8 February 2010, at 08:00AM CET, and that all interested parties are invited to participate in a telephone conference, which will include a presentation, on the same day at 2:00PM CET. The event will be hosted by Hansa Medical’s CEO and President, Søren

    Increase of number of votes in Hansa Medical AB (publ)

    Lund, Sweden, January 31, 2019 – Hansa Medical AB (publ) (Nasdaq Stockholm: HNSA) (“Hansa Medical” or the “Company”), under name change to Hansa Biopharma AB, a biopharmaceutical company focused on inhibition of immunoglobulin G (IgG)-mediated immunopathologies, today announced that the Company’s number of votes has changed as a result of the conversion of 13,142 C shares into ordinary shares during January under Hansa Medical’s long-term incentive program.As of January 31, 2019, the total number of registered and outstanding shares of Hansa Medical totals 40,681,654 of which 39,973,032 are

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Media